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ABSTRACT 
MARGARET ANN STREET: Modification of HIV-1 Protease Inhibitor Pharmacophore 
to Assess Anti-Malarial Properties 
(Under the direction of John Rimoldi) 
 
 
For years, the human immunodeficiency virus type 1 (HIV-1) and malarial 
parasites have both been prevalent in sub-Saharan Africa. Coinfections of HIV-1 and 
malaria are common in areas of geographic overlap as both infections seem to increase 
the severity of the other. HIV-1 treatments have shown to decrease the Plasmodium 
infections resulting in a lower malarial incidence. HIV-1 protease inhibitors target a 
crucial step in the life cycle required for viral maturation and have demonstrated a lower 
level of resistance compared with other therapies. Recent studies have shown the 
treatment of HIV-1 with protease inhibitors has resulted in inhibitory effects against the 
Plasmodium falciparum malaria parasite. With growing resistance to current anti-malarial 
drugs, the need for new compounds is crucial. In an effort to identify the key functional 
group in protease inhibitors responsible for malaria inhibition, the lopinavir analogs were 
designed around blocking the HIV-1 activity. The secondary alcohol required for HIV-1 
activity was modified in each of the designed compounds in an effort to isolate the 
malarial inhibition. The compounds were submitted for biological evaluation in a 
malarial inhibition assay against the chloroquine-sensitive and chloroquine-resistant 
strains of P. falciparum. The modifications of the secondary alcohol within the protease 
inhibitor pharmacophore resulted in a decreased potency against the malaria protozoan, 
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demonstrating a need for further research on how the protease inhibitor targets P. 
falciparum.  
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INTRODUCTION 
 
The human immunodeficiency virus type-1 (HIV-1) is a retrovirus that infects the 
cluster of differentiation 4 positive (CD4+) T-lymphocytes (T-cells) of the immune 
system. This impairs the immune system's ability to fight off infections leaving people 
living with HIV-1 vulnerable to other infections and diseases.1 Infections associated with 
immunodeficiency are known as opportunistic infections as they take advantage of the 
weakened immune system. HIV-1 is a slowly progressing disease that continues to 
damage the immune system from the time of infection until the presence of a high viral 
load and opportunistic infections eventually lead to acquired immunodeficiency 
syndrome (AIDS).2 
Many were skeptical regarding the high HIV-1 prevalence in African countries as 
the World Health Organization (WHO) prevalence maps for HIV-1 in the early 1990s 
showed very low levels in south Africa creating a lack of urgency. The 1990s soon 
became characterized by an HIV-1 epidemic with very high morbidity and over half of 
adult mortalities attributable to HIV-1.3 At the end of 2017, more than thirty-six million 
people were living with HIV-1 and AIDS worldwide. The WHO African region, shown 
in Figure 1, remains the most severely affected with 1 in 25 adults living with HIV-1.4 
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Figure 1: Prevalence of HIV-1 among adults ages 15-49 in 2017 by WHO region4 
 
 
 
Development of HIV Protease Inhibitors 
In the 1990s, few antiretrovirals were available so the primary management for 
HIV-1 was largely based on proper prophylaxis. Drug development focused on targeting 
each stage of the HIV-1 retroviral life cycle, shown in Figure 2. As more antiretrovirals 
were developed, the standard of care progressed from monotherapy to combination 
therapy.5 The most current and most effective AIDS therapy is a form of combination 
therapy known as highly active antiretroviral therapy (HAART). The HAART combines 
the use of an HIV-1 protease inhibitor, reverse transcriptase inhibitor, and/or an integrase 
inhibitor. Protease inhibitors have proven to be one of the most important components in 
combination therapy due to the lower level of resistance compared with other therapies.6 
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Figure 2: Drug Targets within the HIV Life Cycle7 
 
HIV-1 proteases are essential in creating mature infectious viral particles. The HIV-
1 protease is an aspartyl protease meaning it contains an aspartic acid in the active site. 
The protease is assembled in a symmetric homodimer with two identical subunits of 
ninety-nine amino acids.8 The protease peptides have a superimposable secondary 
structure that creates a pocket designed to fit the substrate binding regions. This pocket 
allows the protease to recognize the skewed shape of the peptide rather than targeting a 
specific amino acid sequence. The protease active site is covered by two flexible ß-flaps 
that must be opened to allow the substrate to enter. The polyprotein precursor is cleaved 
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and digested into protease, reverse transcriptase, and integrase. The protease inhibitor 
complexes with the HIV-1 protease, shown in Figure 3, to block the active site preventing 
viral maturation. The secondary hydroxyl group of the inhibitor interacts with the 
protease via hydrogen bonding with the carboxyl group of the active site aspartic 
residues.6  
 
 
Figure 3: HIV-1 protease structure in complex with lopinavir 
From PDB 6DJ19 
 
The pharmacophore of a molecule is the spatial arrangement critical for interactions 
in a specific binding site for a target receptor. Pharmacophores are often considered the 
largest common feature shared among a set of active molecules.10 The majority of FDA 
approved HIV-1 protease inhibitors contain the hydroxyethylamine pharmacophore, 
highlighted in blue in Figure 4, designed to mimic the substrate transition state in order to 
interact with the protease active site. The secondary hydroxyl group of the 
pharmacophore is crucial for its interaction with the carboxyl group of the HIV-1 
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protease active site.6 If the hydroxyethylamine pharmacophore is removed or 
substantially altered, the resulting ligands will not interact with the binding site of the 
target receptor therefore eliminating the inhibitory effects. 
 
 
Figure 4: Nine FDA approved HIV-1 protease inhibitors11 
 
 
Interaction of HIV-1 and Malaria 
HIV-1 and malaria have proven to be two of the deadliest diseases, both of which 
are prevalent in sub-Saharan Africa. According to statistics from 2013, sub-Saharan 
Africa contains only 12% of the global population yet is burdened with 71% of the global 
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HIV-1 infection. Although HIV-1 infection trends in sub-Saharan are declining, almost 
80% of those living with HIV-1 worldwide are located in southern and eastern Africa.12  
Co-infections with HIV-1 and malaria have become common in sub-Saharan Africa 
with each enhancing the other's severity. The geographic overlap between HIV-1 and 
Plasmodium species has contributed to the spread of both diseases and led to an increase 
in coinfections.13 HIV-1 infected individuals are more susceptible to malaria infections 
due to immune deficiency, which should lead to an increase in the frequency of 
coinfections with malaria.14 Malaria infections create an ideal environment for HIV-1 
replication, accelerating the progression of HIV-1. Malaria infections increase CD4+ T-
cell activation to induce a strong inflammatory immune response. With this synergistic 
effect enhancing the harm to the patient, development of treatment options for co-
endemic settings are crucial and the effectiveness of antiretroviral drugs in malarial 
settings needs to be tested.15  
Current treatment options for malaria control are precarious, so recent measures 
have been taken to develop new or to repurpose existing drugs for valuable interventions 
in controlling the spread of infections. All recommended drug combinations for HIV-1 
treatment have been shown to significantly decrease Plasmodium infections with protease 
inhibitors resulting in the lowest clinical malaria incidence.13 Protease inhibitors are 
strong antiretrovirals with effective HIV-1 treatment but have also demonstrated effective 
in vitro activity against some malarial strains of Plasmodium falciparum.15 According to 
a study performed in 2012, the lopinavir-ritonavir combination drug decreased the risk 
for malaria infections by roughly forty percent.16 The protease inhibitor, lopinavir, is 
prepared as a combination formula with ritonavir. Ritonavir is a strong enzyme inhibitor 
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that increases with bioavailability of lopinavir, making lopinavir more effective against 
viral infections.17 Of the protease inhibitors tested, lopinavir, shown in Figure 5, was the 
most potent antimalarial inhibitor, demonstrating a half maximal inhibitory concentration 
(IC50) nearly tenfold below the trough blood concentration achieved with standard 
dosing.18 The inhibitory concentration results indicated lopinavir was one of the most 
promising for antimalarial development, which was the reason lopinavir was chosen for 
this project. 
 
 
Figure 5: Structure and IUPAC name of Lopinavir 
  
(1) 
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MATERIALS AND METHODS 
General Methods 
Each reaction was monitored for consumption of starting material or product 
formation using thin-layer chromatography (TLC) techniques and detection with 
ultraviolet (UV) light at 254 nM (lopinavir is UV active due to the presence of aromatic 
rings). The TLC plates were stained with phosphomolybdic acid (PMA) or potassium 
permanganate and heated to aid visualization of the compound. 
All commercially available starting materials and reagents were purchased at the 
highest commercial quality and used without further purification unless otherwise noted. 
With many of the reagents being sensitive to moisture, all of the reactions were 
performed under standard anhydrous conditions. Standard anhydrous conditions indicate 
the reactions were performed in flame-dried glassware evacuated and cleared with an 
inert blanket of argon while using commercially available anhydrous solvents. Three 
analogs, shown in Figure 6, were synthesized from lopinavir using procedures derived 
from immunochemically equivalent compounds.19 Lopinavir was deprotonated using 
sodium hydride or trichloroacetyl isocyanate and the appropriate alkylating agent was 
added to synthesize the desired analog. 
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Figure 6: Synthesized Analogs of Lopinavir 
 
 
Molecular weight analysis was performed using a Waters Micromass Quattro 
Micro mass spectrometer with either positive (ESI+) or negative (ESI-) electrospray 
ionization. A Bruker 400 MHz Avance Nuclear Magnetic Resonance (NMR) 
spectrometer was used in acquiring the proton (1H) and carbon (13C) NMR spectral data, 
which was then processed using MNova (MestReNova) software. A Teledyne ISCO 
CombiFlash Rf+ PurIon was used to conduct preparative high performance liquid 
(2) 
(3) 
(4) 
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chromatography (HPLC) in separating and purifying the desired compounds from the 
product mixture. The desired compounds were assessed for inhibition against the 
Plasmodium falciparum protozoan using the antimalarial assay conducted by the National 
Center for Natural Product Research (NCNPR) at the University of Mississippi. 
 
 
 
Experimental Methods 
Lopinavir Carbamate 
Under standard anhydrous conditions, 
commercially available lopinavir (100 mg, 
0.159 mmol) was dissolved in 
dichloromethane (1 mL) and cooled in an 
ice bath to 0 ºC. Trichloroacetyl 
isocyanate (40 µL, 0.318 mmol) was slowly added to the solution. The reaction mixture 
was allowed to reach room temperature as it stirred for four hours. The crude product was 
concentrated under reduced pressure to produce lopinavir-o-trichloroacetylcarbamate. 
Potassium carbonate (455 mg, 3.3 mmol), methanol (4.5 mL), and water (1.5 mL) were 
added to the crude product at 0 ºC. The reaction mixture was allowed to stir at 0 ºC for 
one hour and at room temperature for eighteen hours. The mixture was concentrated 
under reduced pressure. Chloroform (100 mL) and water (30 mL) were added to the 
residue. The mixture was transferred to a separatory funnel and extracted 3 times with 20 
mL of chloroform. The organic layers were combined and dried over magnesium sulfate. 
The organic layers were concentrated in a vacuum to give 115 mg of crude product. 
Purification of 50 mg of the crude product was accomplished using RP-HPLC with a 
(2) 
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mobile phase consisting of a water-acetonitrile gradient. The mass of each fraction was 
analyzed, and the product fraction was lyophilized to remove water. From the 50 mg of 
crude material, 24 mg of the desired product was obtained (48% yield). MS (ESI+) m/z = 
694.55 [M+Na]+ 1H NMR (500 MHz, Methanol-d4) δ 7.81 (d, J = 9.2 Hz, 1H), 7.36 – 
7.19 (m, 9H), 7.21 – 7.13 (m, 1H), 7.01 (d, J = 7.4 Hz, 2H), 6.98 – 6.91 (m, 1H), 5.02 
(ddd, J = 8.1, 6.2, 2.3 Hz, 1H), 4.84 (s, 1H), 4.45 (dt, J = 10.1, 5.2 Hz, 1H), 4.33 (d, J = 
11.2 Hz, 1H), 4.15 (d, J = 14.9 Hz, 1H), 4.07 (d, J = 14.9 Hz, 1H), 3.21 – 3.10 (m, 2H), 
3.05 (ddd, J = 11.5, 7.0, 4.0 Hz, 1H), 2.99 – 2.77 (m, 4H), 2.59 (dd, J = 13.6, 9.8 Hz, 
1H), 2.18 (s, 6H), 2.17 (d, J = 10.1 Hz, 1H), 1.89 – 1.75 (m, 2H), 1.73 – 1.64 (m, 1H), 
1.50 (dt, J = 11.2, 6.3 Hz, 1H), 0.91 (d, J = 6.5 Hz, 3H), 0.84 (d, J = 6.7 Hz, 3H). 13C 
NMR (126 MHz, MeOD) δ 170.38, 170.29, 169.61, 157.73, 157.11, 154.35, 138.50, 
137.82, 130.32, 129.21, 129.05, 128.70, 128.01, 127.93, 126.16, 125.73, 124.44, 72.99, 
69.55, 62.59, 51.70, 51.62, 48.16, 47.99, 47.82, 47.65, 47.48, 47.31, 47.14, 40.48, 40.17, 
39.40, 37.84, 37.49, 25.53, 21.17, 18.82, 17.60, 15.05. 
 
Lopinavir Methyl Acetate 
Under standard anhydrous conditions, 
commercially available lopinavir (80 mg, 
0.127 mmol) was dissolved in THF at 
room temperature. Sodium hydride, 60% 
in oil, (24 mg) was added and the mixture 
stirred for one hour at room temperature. Methyl bromoacetate was added and the 
reaction stirred at room temperature for twenty-four hours. The mixture was quenched 
(3) 
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with a 50mM phosphate buffer (sodium and potassium) and stirred at room temperature 
for one hour. The reaction mixture was transferred to a separatory funnel and extracted 4 
times with 10 mL of ethyl acetate. The organic layers were combined and dried with 
magnesium sulfate. The organic layers were concentrated in a vacuum to give 100 mg of 
crude product. The product was then purified using preparative TLC using 5% isopropyl 
alcohol in chloroform. MS (ESI+) m/z = 724.56 [M+Na]+.1H NMR (400 MHz, 
Methanol-d4) δ 7.31 (dd, J = 17.5, 7.2 Hz, 5H), 7.25 (d, J = 4.4 Hz, 5H), 7.23 – 7.16 (m, 
1H), 7.05 – 6.90 (m, 5H), 4.45 (s, 2H), 4.29 (dd, J = 28.5, 13.7 Hz, 3H), 4.19 – 4.11 (m, 
2H), 4.07 (d, J = 14.8 Hz, 1H), 3.78 (s, 3H), 3.66 (s, 2H), 3.55 (d, J = 9.5 Hz, 1H), 3.17 
(s, 2H), 3.15 – 3.01 (m, 1H), 3.04 (s, 1H), 2.97 (dd, J = 13.9, 4.9 Hz, 1H), 2.87 – 2.79 (m, 
3H), 2.70 – 2.59 (m, 1H), 2.37 – 2.25 (m, 1H), 2.19 (d, J = 11.9 Hz, 5H), 2.19 (s, 6H), 
1.92 (s, 0H), 1.84 (t, J = 12.6 Hz, 1H), 1.72 (d, J = 11.3 Hz, 1H), 1.55 (s, 15H), 1.32 (d, J 
= 6.8 Hz, 7H), 0.96 – 0.88 (m, 1H), 0.85 (dd, J = 6.7, 2.5 Hz, 7H).  
  
Lopinavir Methyl Acetic Acid 
 Under standard anhydrous conditions, 
commercially available lopinavir (80 mg, 
0.127 mmol) was dissolved in 
tetrahydrofuran (3 mL) at room 
temperature. Sodium hydride, 60% in oil, 
(19 mg) was added to the solution. The reaction stirred for one hour at room temperature. 
Methyl bromoacetate was added and the reaction mixture continued to stir at room 
temperature for ninety-six hours. Potassium phosphate was added followed by lithium 
hydroxide monohydrate and the reaction mixture stirred at room temperature for an 
(4) 
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additional ninety-six hours. The reaction mixture was concentrated under pressure. 
Approximately six drops of 20% phosphoric acid were added to acidify the aqueous 
residue to a pH of 5-6 and extracted 5 times with 15 mL of chloroform. The organic 
layers were combined and dried over magnesium sulfate and concentrated in a vacuum to 
give 107 mg of crude product. The crude product was purified using preparative TLC 
using isopropyl alcohol, trifluoroacetic acid, and chloroform. MS (ESI-) m/z = 685.42 
[M-H]- 
 
 
Anti-Malarial Bioassay 
The antimalarial screening was completed by the National Center for Natural 
Products at the University of Mississippi. The NCNPR antimalarial screening was funded 
by United States Department of Agriculture, Agricultural Research Service Specific 
Cooperative Agreement, Grant Number 58-6408-1-603. The antimalarial screening tests 
a sample’s ability to inhibit the chloroquine sensitive or chloroquine resistant 
Plasmodium falciparum protozoan. The primary screen tests crude extracts at 15,867 
ng/mL against the D6 P. falciparum strain. The percent inhibitions are calculated relative 
to negative and positive controls. If the extract shows greater than fifty percent inhibition, 
it proceeds to the secondary assay. 
In the secondary assay, the pure column fractions were dissolved to a 
concentration of 2 mg/mL. The samples were tested to determine the half maximal 
inhibitory concentration (IC50) for both the chloroquine-sensitive (D6) and the 
chloroquine-resistant (W2) clones of P. falciparum. Analogues were evaluated for in 
vitro cytotoxicity against mammalian kidney cell line (VERO) up to a concentration of 
 14 
4760 ng/mL via a neutral red assay. The IC50 is reported as the test concentration in 
nanograms per milliliter that provides a fifty percent inhibition of the protozoan relative 
to negative and positive controls. The positive controls in this assay were the antimalarial 
drug controls chloroquine and artemisinin. The selectivity index (SI) is calculated as a 
ratio of VERO IC50 to the IC50 of either D6 or W2 P. falciparum strain. The VERO IC50 
is the concentration at which fifty percent of the viable cells die due to cytotoxicity. A 
high SI is favorable as the compound will have a higher selectivity towards the pathogen 
compared to the host. 
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RESULTS AND DISCUSSION 
 
Three target analogues were successfully synthesized from lopinavir, which include 
lopinavir carbamate, lopinavir methyl acetate, and lopinavir methyl acetic acid. For each 
reaction, the secondary alcohol of lopinavir was targeted for deprotonation in order to add 
the desired group to the product molecule. Lopinavir (1) was deprotonated using sodium 
hydride or trichloroacetyl isocyanate and the appropriate alkylating agent was added to 
form the carbamate (2), methyl acetate (3) and methyl acetic acid (4) analogs. The 
structures of the final products were confirmed using MS and NMR spectrometry.  
The hydroxylethylamine pharmacophore was modified to block the antiretroviral 
activity in an attempt to isolate the antimalarial activity for amplification. If the analogs 
were submitted for HIV-1 assays, the elimination of the hydroxylethylamine 
pharmacophore would likely result in the analogs being devoid of HIV-1 inhibitory 
activity. With the antiretroviral pharmacophore inhibited, the compounds were subjected 
to a biological assay to determine the concentration needed to acquire antimalarial 
activity. The results from the biological evaluation screening, shown in Table 1, indicate 
the modification of the hydroxyl group decreases the inhibitory effects against the 
malaria Plasmodium falciparum. This proves the secondary hydroxyl group is not only 
necessary for the antiretroviral activity but also for the antimalarial activity. The 
unmodified lopinavir demonstrated the greatest potency against both the D6 and W2 
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strains at concentrations of 4.26 µM and 2.1 µM, respectively. Previous in vitro studies 
have the IC50 of lopinavir against the W2 strain as being 2.7 µM, which is relatively high 
compared with its HIV activity of 0.005 µM.20 The modification with the methyl acetate 
and methyl acetic acid demonstrated a decrease in potency for the P. falciparum D6 and 
W2 strains as the concentration needed for inhibition exceeded the limitations of the 
assay. Although the IC50 increased for the methyl acetate and methyl acetic acid, the 
analogs likely still have sufficient antimalarial activity compared to other protease 
inhibitors. Lopinavir has a relatively high activity against malaria compared with other 
HIV-1 protease inhibitors, which average at 17µM.20  
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Compound P. falciparum D6 IC50 
P. falciparum 
D6 SI 
P. falciparum 
W2 IC50 
P. falciparum 
W2 SI 
 
(1) 
2681 >1.8 1324.3 >3.6 
 
(2) 
>4760 1 3563.1 >1.3 
(3) 
>4760 1 >4760 1 
 
(4) 
>4760 1 >4760 1 
Table 1. Antimalarial screening results from NCNPR. All concentrations are in 
nanograms per milliliter. 
 
 
The high SIs calculated for lopinavir at 1.8 and 3.8 demonstrate an achievable 
inhibitory concentration with minimal cytotoxicity effects. Although the screening was 
limited by the concentration range, the values indicate lopinavir methyl acetate and 
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lopinavir methyl acetic acid would require at least a four-fold increase in the drug 
concentration compared with lopinavir. 
All three of the synthesized analogs are increased in size compared with lopinavir 
due to the addition of the larger functional groups. This increase in size could be 
interfering with the interaction of the inhibitor and malaria, causing a decrease in 
inhibitory activity. The change in the hydroxyl group decreases hydrogen bonding which 
likely interferes with the inhibitory interactions with malaria. The lopinavir carbamate 
analog resulted in a better inhibitory concentration compared with the lopinavir acetate 
and lopinavir acetic acid, indicating hydrogen bonding is a crucial interaction. 
 The biological screening is consistent in measuring the potency of the compound 
toward the particular malarial strain without disturbance from other variables, such as cell 
membrane permeability. Each of the analogues should have had the necessary lipophilic 
character, which is shown in Table 2, to penetrate the cell membrane. With this variable 
eliminated, the results from the screening are able to focus exclusively on the inhibitory 
effects for the malarial strains. 
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Compound Molecular Weight ClogP 
 
(1) 
628.81 6.0946 
 
(2) 
671.84 6.127 
(3) 
700.88 6.91 
 
(4) 
686.85 6.0379 
Table 2. Chemical properties of lopinavir and synthesized analogs.  
ClogP estimations from ChemDraw. 
 
 
 Based on the malarial inhibition data, it can be concluded that the secondary 
hydroxyl group is required for malarial inhibition as modification of this functional group 
increased the concentration needed for fifty percent inhibition. This indicates the 
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secondary hydroxy group in the pharmacophore of the protease inhibitor contributes to 
both the antiretroviral activity and the antimalarial activity. If HIV-1 assay data was 
available for these compounds, it would most likely show the analogs devoid of HIV-1 
inhibitory activity. Additional research is needed to validate the importance of the 
hydrogen bonding in malarial inhibition. Analogs need to be synthesized with functional 
groups similar in size to the hydroxyl to explore trends for a lack of hydrogen bonding 
and for an increase in hydrogen bonding. In this research, only the D6 and W2 strains of 
malaria were assayed; however, investigation into the most prominent strains in sub-
Saharan Africa is needed. Research is also needed to determine the protease inhibitor’s 
mechanism of action for inhibiting the varying strains of P. falciparum. 
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